Portfolio

Omlonti®

(omidenepag isopropyl ophthalmic solution) 0.002%

EP2 receptor agonist with a new mechanism of action for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

PDP-716​

Once-daily brimonidine for ocular hypertension and open angle glaucoma utilizing our patented TearAct™ fine resin technology.

SDN-037

Twice daily topical difluprednate for post-surgical inflammation and pain utilizing our patented TJM micellar platform.